This BLISS-LN trial demonstrated the potential of belimumab as an add-on therapy for patients with lupus nephritis; lead investigator Richard Furie discusses why these findings are important for this patient population (8:28).
05-06-2020 | EULAR 2020 | Conference coverage | Video